Eslicarbazepine Acetate Patent Expiration
Eslicarbazepine Acetate is Used for managing partial-onset seizures and absence seizures in patients with epilepsy. It was first introduced by Sumitomo Pharma America Inc
Eslicarbazepine Acetate Patents
Given below is the list of patents protecting Eslicarbazepine Acetate, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Aptiom | US10675287 | Methods of treatment of partial onset seizures using eslicarbazepine acetate | May 06, 2025 | Sumitomo Pharma Am |
| Aptiom | US10695354 | Methods of treatment of partial onset seizures using eslicarbazepine acetate | May 06, 2025 | Sumitomo Pharma Am |
| Aptiom | US10702536 | Methods of treatment of partial onset seizures using eslicarbazepine acetate | May 06, 2025 | Sumitomo Pharma Am |
| Aptiom | US10912781 | Pharmaceutical composition comprising licarbazepine acetate | Oct 23, 2028 | Sumitomo Pharma Am |
| Aptiom | US11364247 | Methods of treatment of partial onset seizures using eslicarbazepine acetate | May 06, 2025 | Sumitomo Pharma Am |
| Aptiom | US5753646 | Substituted dihydrodibenzo/b,f/azepines, method of their preparation, their use in the treatment of some central nervous system disorders, and pharmaceutical compositions containing them |
Jun 27, 2021
(Expired) | Sumitomo Pharma Am |
| Aptiom | US8372431 | Pharmaceutical composition comprising licarbazepine acetate | Apr 17, 2030 | Sumitomo Pharma Am |
| Aptiom | US9206135 | Asymmetric catalytic reduction of oxcarbazepine | Apr 21, 2026 | Sumitomo Pharma Am |
| Aptiom | US9566244 | Pharmaceutical composition comprising licarbazepine acetate | Oct 23, 2028 | Sumitomo Pharma Am |
| Aptiom | US9643929 | Asymmetric catalytic reduction of oxcarbazepine | Apr 21, 2026 | Sumitomo Pharma Am |
| Aptiom | US9750747 | Treatments involving eslicarbazepine acetate or eslicarbazepine | Aug 24, 2032 | Sumitomo Pharma Am |
| Aptiom | US9763954 | Therapeutical uses of eslicarbazepine | Sep 13, 2028 | Sumitomo Pharma Am |
Coming Soon
Patent Strength Analyzer
YesNo
Thank you for your response 🥳
Eslicarbazepine Acetate Generics
Several generic applications have been filed for Eslicarbazepine Acetate. The first generic version for Eslicarbazepine Acetate was by Dr Reddys Laboratories Ltd and was approved on Jun 29, 2021. And the latest generic version is by Lupin Ltd and was approved on Mar 27, 2024.
Given below is the list of companies who have filed for Eslicarbazepine Acetate generic.
1. TORRENT
Torrent Pharmaceuticals Ltd has filed for 4 different strengths of generic version for Eslicarbazepine Acetate. Given below are the details of the strengths of this generic introduced by Torrent.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 600MG | tablet | Discontinued | ORAL | N/A | Feb 27, 2024 |
| 200MG | tablet | Discontinued | ORAL | N/A | Feb 27, 2024 |
| 400MG | tablet | Discontinued | ORAL | N/A | Feb 27, 2024 |
| 800MG | tablet | Discontinued | ORAL | N/A | Feb 27, 2024 |
2. DR REDDYS
Dr Reddys Laboratories Ltd has filed for 4 different strengths of generic version for Eslicarbazepine Acetate. Given below are the details of the strengths of this generic introduced by Dr Reddys.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 800MG | tablet | Prescription | ORAL | AB | Jun 29, 2021 |
| 400MG | tablet | Prescription | ORAL | AB | Jun 29, 2021 |
| 600MG | tablet | Prescription | ORAL | AB | Jun 29, 2021 |
| 200MG | tablet | Prescription | ORAL | AB | Jun 29, 2021 |
3. LUPIN LTD
Lupin Ltd has filed for 4 different strengths of generic version for Eslicarbazepine Acetate. Given below are the details of the strengths of this generic introduced by Lupin Ltd.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 200MG | tablet | Prescription | ORAL | AB | Mar 27, 2024 |
| 400MG | tablet | Prescription | ORAL | AB | Mar 27, 2024 |
| 600MG | tablet | Prescription | ORAL | AB | Mar 27, 2024 |
| 800MG | tablet | Prescription | ORAL | AB | Mar 27, 2024 |
4. HETERO LABS LTD V
Hetero Labs Ltd Unit V has filed for 4 different strengths of generic version for Eslicarbazepine Acetate. Given below are the details of the strengths of this generic introduced by Hetero Labs Ltd V.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 200MG | tablet | Prescription | ORAL | AB | Aug 3, 2023 |
| 400MG | tablet | Prescription | ORAL | AB | Aug 3, 2023 |
| 600MG | tablet | Prescription | ORAL | AB | Aug 3, 2023 |
| 800MG | tablet | Prescription | ORAL | AB | Aug 3, 2023 |
5. ALKEM LABS LTD
Alkem Laboratories Ltd has filed for 4 different strengths of generic version for Eslicarbazepine Acetate. Given below are the details of the strengths of this generic introduced by Alkem Labs Ltd.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 600MG | tablet | Prescription | ORAL | AB | Oct 6, 2023 |
| 200MG | tablet | Prescription | ORAL | AB | Oct 6, 2023 |
| 400MG | tablet | Prescription | ORAL | AB | Oct 6, 2023 |
| 800MG | tablet | Prescription | ORAL | AB | Oct 6, 2023 |
6. APOTEX
Apotex Inc has filed for 4 different strengths of generic version for Eslicarbazepine Acetate. Given below are the details of the strengths of this generic introduced by Apotex.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 200MG | tablet | Discontinued | ORAL | N/A | Dec 7, 2023 |
| 400MG | tablet | Discontinued | ORAL | N/A | Dec 7, 2023 |
| 600MG | tablet | Discontinued | ORAL | N/A | Dec 7, 2023 |
| 800MG | tablet | Discontinued | ORAL | N/A | Dec 7, 2023 |